Will the FDA approve a cure for Type 1 Diabetes before 2033?
I was scrolling through Kalshi markets this morning, and one number really jumped out at me: 34%. That's the current probability traders are giving to the question, "Will the FDA approve a cure for Type 1 Diabetes before 2033?" And honestly, my gut reaction was, "Only 34%?"
When I see a market like this, with such a long timeframe and such a high-impact outcome, my analyst brain immediately starts trying to figure out if the crowd has it right. A 34% chance means that for every dollar you bet on YES, you'd get about $2.94 back if it happens. Conversely, the NO side, currently at 59%, pays out about $1.69. That 59% suggests the market is pretty confident we won't see a cure in the next nine years. But I’m not so sure I agree with that prevailing sentiment. I think there's a strong argument for the YES here, and I’m ready to make it.
This market has seen a decent amount of action, with 8,360 contracts traded. That's not blockbuster volume, but it's enough to show real interest, and the open interest sits at 4,846 contracts. People are putting real money down, signaling they have strong opinions on what the next decade holds for medical breakthroughs. What I find particularly fascinating is that Kalshi has categorized this market under "politics." It's not immediately obvious why a medical approval would be political, but I think it hints at the regulatory hurdles and the potential for public pressure or policy shifts to accelerate a promising treatment, especially for a disease with such a broad impact.
My first thought when considering the 34% "YES" price is always about the definition of "cure." What exactly would the FDA consider a cure for Type 1 Diabetes? Is it a complete reversal, where the body produces insulin naturally and indefinitely without intervention? Or could it be something like a functional cure – perhaps a stem cell therapy that eliminates the need for daily insulin injections, even if some form of long-term monitoring or maintenance is still required? The market's wording, "a cure," is broad enough to leave room for interpretation, and I think that ambiguity might be playing into the lower probability for YES. Regulators are notoriously cautious, and setting a high bar for a "cure" can delay things.
However, here's where my optimism, and my money, comes in. We’re talking about a market that closes on January 1, 2033. That's nearly a decade from now. In the world of biotechnology and medical research, a decade is an eternity. Think about how far CRISPR gene editing has come, or the rapid development of mRNA vaccines, in just the last few years. The pace of scientific discovery is accelerating, and areas like regenerative medicine, particularly islet cell encapsulation and stem cell-derived beta cell replacement, are showing truly exciting progress. Immunotherapies aimed at stopping the autoimmune attack on beta cells are also advancing. We’re not just talking about incremental improvements to insulin delivery; we’re talking about therapies designed to restore the body’s natural function. The clinical trials for these types of interventions are underway right now, not just theoretical concepts.
Furthermore, Type 1 Diabetes is a devastating disease, often diagnosed in children and adolescents, leading to a lifetime of management and significant health complications. There's an enormous unmet medical need and immense pressure from patient advocacy groups and the public for a true solution. This is where the "politics" categorization might actually play in favor of a quicker approval. If a therapy emerges that truly appears safe and effective, and meets a reasonable definition of "cure," I believe there would be significant political and public will to expedite its review process, potentially leveraging accelerated approval pathways that the FDA already has in place for serious conditions with no current cures.
So, when I weigh the inherent challenges of FDA approval and the high bar of a "cure" against the incredible advancements in biotech and the nearly nine-year timeline, I can't help but feel that 34% is a conservative estimate. I see a world where a functional cure, a breakthrough that truly frees people from daily insulin injections and constant glucose monitoring, could very well receive FDA approval before 2033. I'm not saying it's a sure thing – nothing in medicine ever is – but I think the market is underestimating the relentless pace of innovation and the power of human ingenuity when faced with such a profound medical challenge. My money, for now, is leaning heavily on the YES side of this market. I'll be watching the clinical trial news and regulatory updates very closely over the next few years.
